- In February 2022, InBody unveiled the BP 170, an automatic blood pressure monitor that empowers individuals to self-record and monitor essential health metrics from the comfort of their homes. This innovative device offers a convenient solution for users to track their blood pressure readings and manage their cardiovascular health more effectively. With its user-friendly design, the BP 170 enhances personal health management by making vital monitoring accessible and straightforward
- In January 2022, Aktiia announced the launch of its 24/7 blood pressure monitor in the United States, representing the next generation of clinical wearables tailored for both patients and healthcare professionals. While consumer wearables have faced challenges in gaining acceptance and trust within the healthcare community—evidenced by the fact that 81% of physicians would not base treatment decisions on consumer wearable data—physicians across Europe are already leveraging Aktiia's technology to personalize patient care. This innovative device aims to bridge the gap between consumer health tracking and clinical reliability, enhancing patient outcomes through continuous monitoring
- In June 2020, MGC Diagnostics, based in the U.S., entered into a distribution agreement with Monitored Therapeutics, Inc. (MTI), also located in the U.S. Under this partnership, MGC Diagnostics will leverage its expertise in diagnostic equipment and cardiopulmonary products to provide in-home solutions for patients. This collaboration aims to support medical professionals by enhancing access to advanced diagnostic tools in a home care setting
- In 2020, Cortex introduced the Wattbike AtomX, heralded as the world's smartest indoor bike. This innovative product is designed for comprehensive analysis, enabling users to monitor heartbeats, assess lung function, and examine both vascular and metabolic systems. The Wattbike AtomX represents a significant advancement in fitness technology, providing valuable insights for health and performance evaluation
Frequently Asked Questions
The market is segmented based on Segmentation, By Product (Single-Photon Emission Computed Tomography (SPECT), Cardiopulmonary Exercise Testing (CPET) Systems, Echocardiogram, Pulse Oximeters, Stress Blood Pressure Monitors, and Others), Application (Oxygen Uptake, Carbon Dioxide, Minute Ventilation, and Anaerobic Threshold), End-User (Diagnostic Centers, Ambulatory Centers, Clinics and Hospitals, and Others) – Industry Trends and Forecast to 2031
.
The Global Cardiopulmonary Exercise Testing Market size was valued at USD 3.67 USD Billion in 2023.
The Global Cardiopulmonary Exercise Testing Market is projected to grow at a CAGR of 4.1% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
